MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
New Afrezza Website is Live
Afrezza®, the only inhaled rapid-acting mealtime insulin in the U.S. commercialized by MannKind, has launched a new website. The site includes a fresh design for easier access to the answers you need, a new blog feature, and an expanded FAQ list. For more information, visit www.afrezza.com
|Sep 24, 2018||MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients… More|
|Sep 13, 2018||Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics… More|
|Sep 04, 2018||United Therapeutics and MannKind Announce Collaboration for Pulmonary Hypertension Products… More|
|Aug 29, 2018||MannKind Corporation to Present at Upcoming Conferences… More|
If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.